Jazz Pharmaceuticals vs Regeneron Pharmaceuticals
JAZZ and REGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAZZ and REGN compare
Regeneron Pharmaceuticals is the larger company, worth 6.3 times as much as Jazz Pharmaceuticals ($98.4B against $15.6B).
On earnings, Regeneron Pharmaceuticals is cheaper: it trades at 21.0× trailing earnings, against 78.3× for Jazz Pharmaceuticals.
Regeneron Pharmaceuticals grew revenue faster over the last twelve months (18.6% versus 13.5% for Jazz Pharmaceuticals).
Regeneron Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 28.5% compared with 4.4% at Jazz Pharmaceuticals.
Regeneron Pharmaceuticals pays a dividend yielding 0.39%; Jazz Pharmaceuticals does not pay one.
Regeneron Pharmaceuticals scores higher on the StockData Score (16 against 7 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAZZ | REGN |
|---|---|---|
| Size and price | ||
| Market cap | $15.6B | $98.4B |
| Share price | $240.37 | $951.19 |
| Change, 1 year | 75.3% | 41.0% |
| Change, 5 years | 87.2% | 45.7% |
| Beta (5Y) | 0.53 | 0.62 |
| Employees | 2,890 | 15K |
| StockData Score | ||
| Total score | 7 | 16 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 3 | 4 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 78.3× | 21.0× (better) |
| P/S | 3.3× (better) | 5.8× |
| P/B | 3.7× | 2.9× (better) |
| EV/EBITDA | 43.0× | 16.9× (better) |
| P/FCF | 9.6× (better) | 25.7× |
| PEG | – | 7.60 |
| FCF yield | 10.4% (better) | 3.9% |
| Fair value | $110.53 | $887.42 |
| Margin of safety | −117% | −7.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.5% | 18.6% (better) |
| Revenue growth, 5Y average | 12.5% (better) | 11.0% |
| Net income growth (TTM) | – | 5.2% |
| EPS growth (TTM) | – | 8.4% |
| EPS growth, 5Y average | – | 6.3% |
| Profitability | ||
| Operating margin | 9.0% | 28.8% (better) |
| Net margin | 4.4% | 28.5% (better) |
| FCF margin | 34.4% (better) | 22.6% |
| Return on equity | 5.1% | 14.9% (better) |
| Return on invested capital | 4.5% | 16.3% (better) |
| Financial health | ||
| Debt / equity | 1.33 | 0.06 (better) |
| Net debt / EBITDA | 6.37 (better) | −1.36 |
| Interest coverage | – | 104× |
| Current ratio | 1.82 | 3.35 (better) |
| Altman Z-score | 1.97 | 7.79 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.39% |
| Payout ratio | – | 8.0% |
| Buyback yield | – | 2.1% |
| Shareholder yield | 0.00% | 2.4% (better) |
| Ownership | ||
| Held by institutions | 99.2% | 88.5% |
| Held by insiders | 3.4% | 3.7% |
| Insider net buying, 12 months | −$67.1M | −$57.4M (better) |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 9.3% | 2.2% |
Go deeper
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
- REGN stock overview
- REGN income statement
- REGN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.